$16.53
1.10%
Nasdaq, Wed, Dec 24 2025
ISIN
US0080641071
Symbol
AVTE

Aerovate Therapeutics Inc Stock price

$16.53
+4.38 36.05% 1M
+6.05 57.73% 6M
-76.22 82.18% YTD
-74.47 81.84% 1Y
-960.32 98.31% 3Y
-782.52 97.93% 5Y
-782.52 97.93% 10Y
-782.52 97.93% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.18 1.10%
ISIN
US0080641071
Symbol
AVTE
Industry

Key metrics

Basic
Market capitalization
$760.5m
Enterprise Value
$561.5m
Net debt
positive
Cash
$198.9m
Shares outstanding
32.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.2
Financial Health
Equity Ratio
95.2%
Return on Equity
-91.1%
ROCE
-36.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-64.9m | -
EBIT
$-65.0m | $-100.6m
Net Income
$-65.3m | $-96.9m
Free Cash Flow
$-72.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
27.6% | -
EBIT
27.8% | -35.4%
Net Income
22.9% | -39.1%
Free Cash Flow
3.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-2.2
Short interest
1.2%
Employees
-
Rev per Employee
-
Show more

Is Aerovate Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Aerovate Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Aerovate Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Aerovate Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Aerovate Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
8% 8%
-
- Research and Development Expense 46 46
34% 34%
-
-65 -65
28% 28%
-
- Depreciation and Amortization 0.03 0.03
90% 90%
-
EBIT (Operating Income) EBIT -65 -65
28% 28%
-
Net Profit -65 -65
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aerovate Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focus on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake in July 27, 2018 and is headquartered in Boston, MA.

Head office United States
CEO Tom Frohlich
Founded 2018
Website jadebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today